Related Experiment Video
Updated: Jun 1, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease: Clinical Evidence and Potential Adverse Events
Ashish Upadhyay1, Lalarukh Haider2
1Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA.
Abstract:
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) globally and is associated with an increased risk of developing cardiovascular disease (CVD). DKD management requires a multipronged approach to decrease the progression of CKD and CVD. Mineralocorticoid receptor antagonists (MRAs) added to renin-angiotensin-aldosterone system blockade and sodium-glucose cotransporter 2 inhibitor therapy reduce the incidence of cardiovascular outcomes and progression of CKD. This review examines the cardiorenal benefits of MRAs and summarizes evidence on potential risks for acute kidney injury, hyperkalemia, and sexual dysfunction for steroidal and nonsteroidal MRAs.
Insights
Mineralocorticoid receptor antagonists (MRAs) help manage diabetic kidney disease (DKD) and reduce risks of chronic kidney disease (CKD) and cardiovascular disease (CVD). This review covers their cardiorenal benefits and potential side effects.
Area of Science:
- Nephrology
- Cardiology
- Endocrinology
Background:
- Diabetic kidney disease (DKD) is a primary cause of chronic kidney disease (CKD) and increases cardiovascular disease (CVD) risk.
- Effective DKD management necessitates strategies to slow CKD and CVD progression.
Purpose of the Study:
- To review the cardiorenal advantages of mineralocorticoid receptor antagonists (MRAs).
- To summarize the risks associated with steroidal and nonsteroidal MRAs, including acute kidney injury, hyperkalemia, and sexual dysfunction.
Main Methods:
- Literature review of studies on MRAs in DKD management.
- Analysis of evidence regarding cardiorenal outcomes and adverse events.
Main Results:
- MRAs, when combined with renin-angiotensin-aldosterone system blockade and SGLT2 inhibitors, reduce CKD progression and cardiovascular events.
- Evidence on the specific risks of MRAs, such as acute kidney injury and hyperkalemia, is examined.
Conclusions:
- MRAs offer significant cardiorenal benefits in patients with DKD.
- Understanding and monitoring potential risks are crucial for optimizing MRA therapy in DKD.
More Related Videos
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hormonal Regulation
Antihypertensive Drugs: Potassium-Sparing Diuretics
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Action of Diuretics